DescriptionThis comprehensive reference work, updated from the first edition, brings together the knowledge and expertise of contributors from around the world. It includes new topics such as prostaglandin synthetase enzyme, new synthetic eicosanoids, innovative analytical methods, the influence of cytokines in the regulation of synthesis and actions, newer eicosanoids that influence the cardiovascular system, and newly discovered roles in reproduction and interactions with nitric oxide.
This book satisfies a surge of interest in prostaglandins—NSAIDS (e.g. aspirin) are the biggest selling drugs of all time, and the field has been refreshed by the advent of new types (selective COX-2 inhibitors, anti-leukotiene drugs).
Preface from Prostaglandins.
Section One: Biosynthesis and Metabolism
1. Perspectives on the Biosynthesis and Metabolism of Eicosanoids (Robert C. Murphy, Rebecca C. Bowers, Jennifer Dickinson and Karin Zemski-Berry).
2. Control of Eicosanoid Production by Cellular and Secreted Phospholipase A2 (Marise Andreani, Jean-Luc Olivier and Gilbert Béréziat).
3. Mechanisms of PGH synthase-1 (COX-1) activity and role of radical states (Carol Deby and Ginette Deby-Dupont ).
4. Regulation and Function of Prostaglandin Synthase 2/Cyclooxygenase II (Harvey R. Herschman).
5. Mammalian Lipoxygenases (Shozo Yamamoto, Hiroshi Suzuki, Natsuo Ueda, Yoshitaka Takahashi and Tanihiro Yoshimoto).
6. Biosynthesis and Biological Effects of 5-oxo-ETE and other Oxoeicosatetraenoic Acids (William S. Powell).
7. Synthetic Eicosanoids (Norrie. H. Wilson).
Section Two: Analytic al Methods
8. Perspectives of Analytical Methods for Eicosanoids (Jay Y. Westcott and Angelo Sala).
9. Enzyme Immunoassays of Metabolites and Enzymes Using Acetylcholinesterase as label (Christophe Créminon and Jacques Maclouf).
10.Bioassay of Eicosanoids (Robert L. Jones).
11. Gas Chromatography and Mass Spectometry in Eicosanoid Analysis (Michinao Mizugaki, Takanori Hishinuma, Naoto Suzuki).
12. Time-resolved Fluoroimmunoassay in Eicosanoid Analysis (Werner Schlegel and Harald John).
Section Three: Biochemical and Molecular Pharmacology
13. Perspectives and Clinical Significance of the Biochemical and Molecular Pharmacology of Eicosanoids (Subhash P. Khanapure and L. Gordon Letts).
14. Eicosanoid Antagonists (Kiyoshi Yasui and Akinori Arimura).
15. Biosynthesis and Degredation of Anandamide, an Endogenous Ligand of Cannabinoid Receptors (Natsuo Ueda and Dale G. Deutsch).
16. Inhibitors of Eicosanoids (K. D. Rainsford).
17. Biology and Chemistry of Products of the Isoprostane Pathway (L. Jackson Roberts, II, and Jason D. Morrow).
18. Insight into Prostanoid Functions; lessons from receptor-knockout mice (Yukihiko Sugimoto, Shuh Narumiya and Atsushi Ichikawa).
Section Four: Immunology, Endocrinology and Metabolic Regulation
19. Perspectives and Clinical Significance of Eicosanoids in Immunology, Endocrinology and Metabolic Regulation (Milan R. Henzl).
20. Prostaglandins and the Immune Response (Diana C. Fleming and Rodney W. Kelly).
21. Leukotrienes in Aspirin-intolerant Asthma (Anthony P. Sampson and Stephen T. Holgate).
22. Essential Fatty Acids (Yoeju Min and Michael A. Crawford).
23. Endothelial Secretory Function and Atherothrombosis (Stefan Chlopicki and Richard J. Gryglewski).
24. Molecular Regulation of Pancreatic Islet Prostaglandin Sythesis and Its Relevance to Diabetes Mellitus (R. Paul Robertson).
25. Prostaglandins, Leukotrienes and Bone (Carol C. Pilbeam and Lawrence G. Raisz).
26. Aging and Prostaglandins (A. Hornych).
Section Five: Inflammation
27. Perspectives and Clinical Significance of Eicosanoids in Pain and Inflammation (Burkhard Hinz and Kay Brune).
28. Anti-Inflammatory Steroids (Françoise Russo-Marie).
29. Eicosanoids and Algesia in Inflammation (Lynne Murray, Henry Sarau and Kristen E. Belmonte).
30. Cyclooxygenase-2 in Cancer (Ovidiu C. Trifan and Jaime L. Masferrer).
31. Cytokines and Eicosanoids in Arthritis (K. D. Rainsford).
Section Six: Circulatory Systems
32. Prespectives and Clinical Significance of Eicosanoids in the Circulatory System (James B. Lee).
33. Aspirin and Activated Platelets (Artur-Aron Weber).
34. Generation of Vasoactive Prostanoids by the Cyclooxygenase-2 Pathway in the Cardiovascular System of the Rat (P. J. Kadowitz, S. R. Baber, M. M. Mazim, M. Keebler, H. C. Champion, T. J. Bivalacqua, D. B. McNamara and A. L. Hyman).
35. Eicosanoid Generation and Effects in Cardiac Muscle and Coronary Vessels (Karsten Schrör).
Section Seven: Digestive System
36. Perspective and Clinical Significance of Eicosanoids in the Digestive System (Chi Hin Cho, Joshua Ka Shun Ko and Marcel Wing Leung Koo).
37. Eicosanoids and Liver Regeneration (David A. Rudnick and Louis J. Muglia).
38. Eicosanoids and the Intestine (Klaus Bukhave and Jørgen Rask-Madsen).
39. Eicosanoids and Stomach Physiology (Brigitta M. Peskar).
Section Eight: Nervous System
40. Perspectives and Clinical Significance of Arachidonic Acid Release, Action and Metabolism In the Nervous System (Christopher D. Breder).
41. Eicosanoid Pathways in the Aging of the Central Nervous System (Hari Manev and Tolga Uz).
42. Arachidonate Metabolites in the Neurophysiological System: The Fever Pathway (Ji Zhang and Serge Rivest).
43. Prostanoids in Pain (Tony L. Yaksh, Patrick W. Mantyh and Camilla I. Svensson).
44. Eicosanoids: Roles in the Pathophysiology of Cerebral Ischemia (Robert W. Hickey and Steven H. Graham).
45. NSAIDs in the Treatment of Alzheimer’s Disease (Paul S. Aisen).
46. Prostaglandins and Eicosanoids (A.I.M. Glen and B.M. Ross).
47. Essential Fatty Acids: Eicosanoid Precursors in the Treatment of Huntington’s Disease (Krishna Vaddadi).
Section Nine: Conclusions and Correlations
48. Perspectives and Clinical Significance of Eicosanoids in Obstetrics and Gynaecologic Practice (I. Z. MacKenzie).
49. Prostaglandins and Male Reproductive Physiology (Rodney W. Kelly).
50. Prostaglandin F2: The Luteolytic Hormone (John A. McCracken).
51. Prostaglandins in Implantation (Norman L. Poyser).
52. Parturition and the Clinical Interruption of Pregnancy (S. Cowan and A.A. Calder).
53. Foetal and Neonatal Ductus Arteriosus (Kazuo Momma).
Section Ten: Conclusions and Correlations
54. Biochemical Interactions of Platelet-Activating Factor with Eicosanoids (Joseph T. O’Flaherty and Robert L. Wykle).
55. Eicosanoid Precursors as Pharmaceuticals (David F. Horrobin).
56. Pharmaceutical Exploitation: cyclooxygenase and lipoxygenase inhibitors (Paola Patrignani and Maria G. Sciulli).
57. Pharmaceutical Exploitation: Eicosanoids and their Analogs (David F. Woodward and June Chen).
"…it serves to effectively communicate the most current information on eicosanoids in an understandable manner.” (E-STREAMS, September 2004)